A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma

Exclusion Criteria

• •Pregnant or lactating females
• •Peripheral neuropathy ≥ to grade 2 of the NCI CTC.
• •Prior history of malignancy unless subject has been free of disease for ≥ 3 years
• •Lab abnormality: Absolute neutrophil count (ANC) \<1,000 cells/mm\^3 (1.0 x 10\^9/L)
• •Lab abnormality: Platelet count \<50,000/mm\^3 (50.0 x 10\^9/L)
• •Lab abnormality: Serum creatinine \>3.0 mg/dL (265 µmol/L)
• •Lab abnormality: Serum glutamic oxaloacetic transaminase (SGOT) /Aspartate aminotransferase (AST) or Serum glutamic pyruvic transaminase (SGPT)/Alanine transaminase (ALT) \>3.0 x upper limit of normal (ULN)
• •Lab abnormality: Serum total bilirubin \> 2.0 mg/dL (34 µmol/L)